Dermata Therapeutics Inc. (DRMAW)
Dermata Therapeutics Statistics
Share Statistics
Dermata Therapeutics has 5.43M shares outstanding. The number of shares has increased by -92.84% in one year.
| Shares Outstanding | 5.43M |
| Shares Change (YoY) | -92.84% |
| Shares Change (QoQ) | -97.86% |
| Owned by Institutions (%) | 1.96% |
| Shares Floating | 3.99M |
| Failed to Deliver (FTD) Shares | 51 |
| FTD / Avg. Volume | 0.37% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Dermata Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Dermata Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1602.58, with a Debt / Equity ratio of 0.
| Current Ratio | 1602.58 |
| Quick Ratio | 1602.58 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.54B |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 95.69% in the last 52 weeks. The beta is 0.58, so Dermata Therapeutics's price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | 95.69% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 41.43 |
| Average Volume (20 Days) | 13.75K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -12.51B |
| Net Income | -12.29B |
| EBITDA | -12.51B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8032.22 |
Balance Sheet
The company has 3.16M in cash and 0 in debt, giving a net cash position of 3.16M.
| Cash & Cash Equivalents | 3.16M |
| Total Debt | 0 |
| Net Cash | 3.16M |
| Retained Earnings | -65.68B |
| Total Assets | 3.53B |
| Working Capital | 3.16B |
Cash Flow
In the last 12 months, operating cash flow was -11.16B and capital expenditures 0, giving a free cash flow of -11.16B.
| Operating Cash Flow | -11.16B |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.16B |
| FCF Per Share | -7297.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRMAW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for DRMAW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -24.96 |
| Piotroski F-Score | 3 |